More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval

Closing Down Jardiance’s Lead

AstraZeneca’s SGLT2 inhibitor produced 50% growth in Q1, and its new chronic kidney disease approval will give it an edge over Lilly and Boehringer’s Jardiance.

AZ building
Farxiga has emerged as the company's star performer in its cardiovascular, renal and metabolism franchise. • Source: Alamy

AstraZeneca’s SGLT2 inhibitor Farxiga is already a big hit in heart failure but is now set to bring in even more revenues thanks to a first-in-class approval in chronic kidney disease (CKD). 

The US Food and Drug Administration gave the green light for Farxiga (dapagliflozin) on 30 April as a treatment to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip